Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

ted in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, AMRIX(TM) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results including the FENTORA clinical trials discussed herein; prospects for regulatory approval, including approval of the FENTORA sNDA and the timing of the FDA's review period for this submission; manufacturing development and capabilities; market prospects for its products; sales and earnings guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... of rod-shaped metal nanoparticles in water with ultrasound and ... bits. Why? No one yet knows exactly. But researchers ... have clocked their speedand it,s fast. At up to ... faster than any nanoscale object submerged in liquid ever ... opened up the possibility that they could be used ...
(Date:7/22/2014)... 22, 2014 Automated cell culture systems ... of cell culture. They allow production of optimum cells ... researchers in drug discovery and industries and biopharmaceutical companies. ... production, iPSC research, cryobanking, cell-based assays, and cellular expression ... , Analysts forecast the Global Cell Culture market ...
(Date:7/22/2014)... (NASDAQ: NEOG ) announced today that revenues ... increased 19% from the previous year to $247,405,000. Fiscal ... year,s $27,190,000. Adjusted for a 3-for-2 stock split effective ... year were $0.76, compared to $0.75 a year ago. ... year established new all-time highs for the 32-year-old company. ...
(Date:7/22/2014)... 22, 2014 Hussey Copper , a ... antimicrobial copper announces Pullman Regional Hospital,s conversion of ... antimicrobial solid touch surface, at a nominal cost.  This ... E-coli and other bacteria within 2 hours of exposure 1 ... bacteria and infectious diseases in its facilities. ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... ON, April 3 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... months ended February 29, 2008. All dollar amounts referenced ... February 29, 2008, our cash and cash equivalents totaled ... We incurred a net loss for the three ...
... BALTIMORE, April 3, 2008 Alba Therapeutics Corporation,today ... its Chief Executive,Officer (CEO) and a member of ... Partner with SV Life Sciences Advisors, LLC. Previously, ... of the senior management team for several,successful entrepreneurial ...
... LEEDS Standards for Sustainable Development, PLEASANTON, Calif., ... announced the opening of its new research facility,at ... represents the final phase of consolidation of RMD,s ... now houses close to 500,employees, including 120 members ...
Cached Biology Technology:Vasogen Announces First Quarter 2008 Results 2Vasogen Announces First Quarter 2008 Results 3Vasogen Announces First Quarter 2008 Results 4Vasogen Announces First Quarter 2008 Results 5Vasogen Announces First Quarter 2008 Results 6Vasogen Announces First Quarter 2008 Results 7Vasogen Announces First Quarter 2008 Results 8Vasogen Announces First Quarter 2008 Results 9Vasogen Announces First Quarter 2008 Results 10Vasogen Announces First Quarter 2008 Results 11Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 3
(Date:7/22/2014)... has shown squirrels have adapted to New York City,s ... if not better, than their fellow squirrels in the ... Department of Environment & Agriculture, led the study that ... behaviour in urban environments and prevent unnecessary responses when ... on the footpath. , "As we rapidly increase ...
(Date:7/22/2014)... as a world-famous vacation spot with natural tourism resources, a ... The Korea Institute of Geoscience and Mineral Resources (KIGAM) indicated ... volcanic eruption was evident 5,000 years ago. That is the ... spewed out of a volcano 5,000 years ago in the ... the whole peninsula. , The research team led by Dr. ...
(Date:7/22/2014)... , July 22, 2014 NXT-ID, Inc., ... growing m-commerce market, announces its next generation smart wallet, ... consumer oriented television show that airs on the ... NewsWatch regularly features top technology products ... 31st on the History Channel (6:00-6:30am ET/PT) and ...
Breaking Biology News(10 mins):New York squirrels are nuts about city life 2Jeju Island is a live volcano 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 3
... Thirty to fifty percent of the global conversion of nutrients ... of the National Academy of Science of the United States ... state that this conversion is not carried out by denitrifying ... Nitrogen compounds act as fertilizers and are the ecological basis ...
... with variant Creutzfeldt-Jakob (vCJD) prions may no longer be ... a transfusion. Pall Corporation (NYSE: PLL) announced today the ... Prion Reduction Filter System. It is the first and ... the causative agent of vCJD from red cells, the ...
... only three months after deciding to create an ... trial registry and results database using an independent ... trials can be accessed by anyone, anywhere, with ... give patients and healthcare providers ready access to ...
Cached Biology News:Anammox bacteria produce nitrogen gas in oceans' snackbar 2Anammox bacteria produce nitrogen gas in oceans' snackbar 3First technology to remove prions that cause vCJD from blood launched 2First technology to remove prions that cause vCJD from blood launched 3First technology to remove prions that cause vCJD from blood launched 4Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Biology Products: